iBio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by iBio, Inc. (formerly iBioPharma, Inc.) on September 15, 2009, covering events occurring on September 10 and September 14, 2009. The company is incorporated in Delaware and operates in the life sciences sector.
Key Financial Metrics and Capital Events
- Capital Raise: On September 10, 2009, the Company completed a private placement of approximately 4,615,385 shares of common stock.
- Purchase Price: $0.65 per share.
- Gross Proceeds: Approximately $3,000,000.
- Investor Type: Accredited investors.
- Registration Status: Shares were sold unregistered under Section 4(2) of the Securities Act and Regulation D. A shelf registration statement for resale is to be filed within 30 days of closing.
- Other Metrics: The filing does not provide specific data on revenue, profit, cash flow, margins, debt, or liquidity positions.
Material Changes and Management Updates
- Executive Appointment: On September 14, 2009, Frederick Larcombe was appointed Chief Financial Officer, effective immediately.
- Background: Mr. Larcombe brings experience from Crimson Partners, Xenomics Inc., FermaVir Pharmaceuticals, Inc., and MicroDose Therapeutics. He will continue to serve as a principal of Crimson Partners while acting as CFO.
- Corporate Name: The filing notes the former name was iBioPharma, Inc.
Guidance, Risks, and Contingencies
The filing does not contain forward-looking guidance, revenue outlook, or specific risk factors beyond standard securities law disclosures. The primary contingency noted is the requirement to file a shelf registration statement for the resale of the newly issued shares within 30 days of the September 10 closing date. Until such registration is effective or an exemption applies, the shares cannot be offered or sold in the United States.
Investor Verification Checklist
- Verify the effectiveness of the shelf registration statement filed for the resale of the 4,615,385 shares.
- Confirm the utilization of the $3,000,000 gross proceeds raised in the private placement.
- Review the full text of the Subscription Agreement (Exhibit 10.1) and Registration Rights Agreement (Exhibit 10.2) for specific covenants.
- Assess the impact of the new CFO appointment on the company's financial reporting and strategic direction.